A Visionary Approach to Uveitis: Tarsier Pharma’s Disruptive Innovation

In this OIS Podcast episode, host Dr. Robert Rothman sits down with Daphne Haim-Langford, PhD, Founder & CEO of Tarsier Pharma, and Ashley Kline, Chief Commercial Officer, to discuss their groundbreaking approach to uveitis treatment. Tarsier’s lead candidate, TRS01, is a first-in-class bio-inspired therapy designed to control inflammation without raising intraocular pressure, a major complication of steroid treatments. With a unique mechanism of action that modulates macrophages and reduces inflammation, this novel drug has the potential to redefine uveitis and glaucoma care. In this episode, you’ll learn: 🔹 How Tarsier’s bio-inspired molecule is changing the game in ophthalmology. 🔹 Why steroids, despite being the standard of care, can be problematic for uveitis patients. 🔹 The challenges of scaling manufacturing and securing regulatory approval for novel ophthalmic treatments. 🔹 Insights from Ashley Kline on the commercial strategy for launching Tarsier’s therapy. 🔹 How Dr. Rothman sees this innovation reshaping ophthalmology and glaucoma treatment. 🎧 Tune in to hear how Tarsier Pharma is working to bring a safer, more effective treatment to market!

You can listen to A Visionary Approach to Uveitis: Tarsier Pharma’s Disruptive Innovation online on Radio and Podcast. Open the player on this page to stream the available audio.

A Visionary Approach to Uveitis: Tarsier Pharma’s Disruptive Innovation is an episode from OIS Podcast by OIS Podcast.

This episode is 29:05 long.

This episode was published on Feb 14, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from OIS Podcast when more episodes are available from the podcast feed.